Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 303

1.

Vps11 and Vps18 of Vps-C membrane traffic complexes are E3 ubiquitin ligases and fine-tune signalling.

Segala G, Bennesch MA, Ghahhari NM, Pandey DP, Echeverria PC, Karch F, Maeda RK, Picard D.

Nat Commun. 2019 Apr 23;10(1):1833. doi: 10.1038/s41467-019-09800-y.

2.

The sensitivity to Hsp90 inhibitors of both normal and oncogenically transformed cells is determined by the equilibrium between cellular quiescence and activity.

Echeverria PC, Bhattacharya K, Joshi A, Wang T, Picard D.

PLoS One. 2019 Feb 6;14(2):e0208287. doi: 10.1371/journal.pone.0208287. eCollection 2019.

3.

Iron- or Palladium-Catalyzed Reaction Cascades Merging Cycloisomerization and Cross-Coupling Chemistry.

Gomes F, Echeverria PG, Fürstner A.

Chemistry. 2018 Nov 13;24(63):16814-16822. doi: 10.1002/chem.201803360. Epub 2018 Oct 18.

PMID:
30183112
4.

High Prevalence of Sarcopenia in HIV-Infected Individuals.

Echeverría P, Bonjoch A, Puig J, Estany C, Ornelas A, Clotet B, Negredo E.

Biomed Res Int. 2018 Jul 12;2018:5074923. doi: 10.1155/2018/5074923. eCollection 2018.

5.

High risk and probability of progression to osteoporosis at 10 years in HIV-infected individuals: the role of PIs.

Negredo E, Langohr K, Bonjoch A, Pérez-Alvárez N, Estany C, Puig J, Rosales J, Echeverría P, Clotet B, Gómez G.

J Antimicrob Chemother. 2018 Sep 1;73(9):2452-2459. doi: 10.1093/jac/dky201.

PMID:
29860519
6.

Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV-1-infected subjects with dyslipidaemia.

Echeverría P, Bonjoch A, Puig J, Ornella A, Clotet B, Negredo E.

HIV Med. 2017 Nov;18(10):782-786. doi: 10.1111/hiv.12530. Epub 2017 Jul 3.

PMID:
28671337
7.

Asymmetric Transfer Hydrogenation of (Hetero)arylketones with Tethered Rh(III)-N-(p-Tolylsulfonyl)-1,2-diphenylethylene-1,2-diamine Complexes: Scope and Limitations.

Zheng LS, Llopis Q, Echeverria PG, Férard C, Guillamot G, Phansavath P, Ratovelomanana-Vidal V.

J Org Chem. 2017 Jun 2;82(11):5607-5615. doi: 10.1021/acs.joc.7b00436. Epub 2017 May 22.

PMID:
28472889
8.

Variable endothelial cell function restoration after initiation of two antiretroviral regimens in HIV-infected individuals.

Echeverría P, Gómez-Mora E, Roura S, Bonjoch A, Puig J, Pérez-Alvarez N, Bayés-Genís A, Clotet B, Blanco J, Negredo E.

J Antimicrob Chemother. 2017 Jul 1;72(7):2049-2054. doi: 10.1093/jac/dkx074.

PMID:
28369542
9.

Prospective Study to Assess Progression of Renal Markers after Interruption of Tenofovir due to Nephrotoxicity.

Bonjoch A, Echeverría P, Perez-Alvarez N, Puig J, Estany C, Clotet B, Negredo E.

Biomed Res Int. 2016;2016:4380845. doi: 10.1155/2016/4380845. Epub 2016 Dec 18.

10.

Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals.

Negredo E, Estrada V, Domingo P, Gutiérrez MD, Mateo GM, Puig J, Bonjoch A, Ornelas A, Echeverría P, Estany C, Toro J, Clotet B.

J Antimicrob Chemother. 2017 Mar 1;72(3):844-849. doi: 10.1093/jac/dkw504.

PMID:
27999056
11.

Arterial oxygen saturation and heart rate after birth in newborns with and without maternal bonding.

Bancalari A, Araneda H, Echeverría P, Alvear M, Romero L.

Pediatr Int. 2016 Oct;58(10):993-997. doi: 10.1111/ped.12991. Epub 2016 Jun 21.

PMID:
27037834
12.

Synthetic Studies toward the C14-C29 Fragment of Mirabalin.

Cornil J, Echeverria PG, Reymond S, Phansavath P, Ratovelomanana-Vidal V, Guérinot A, Cossy J.

Org Lett. 2016 Sep 16;18(18):4534-7. doi: 10.1021/acs.orglett.6b02162. Epub 2016 Sep 7.

PMID:
27602486
13.

Impact of protease inhibitors on the evolution of urinary markers: Subanalyses from an observational cross-sectional study.

Bonjoch A, Puig J, Pérez-Alvarez N, Juega J, Echeverría P, Clotet B, Romero R, Bonet J, Negredo E.

Medicine (Baltimore). 2016 Aug;95(32):e4507. doi: 10.1097/MD.0000000000004507.

14.

An Iron-Catalyzed Bond-Making/Bond-Breaking Cascade Merges Cycloisomerization and Cross-Coupling Chemistry.

Echeverria PG, Fürstner A.

Angew Chem Int Ed Engl. 2016 Sep 5;55(37):11188-92. doi: 10.1002/anie.201604531. Epub 2016 Jul 8.

PMID:
27392133
15.

Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials.

Borges ÁH, Lundh A, Tendal B, Bartlett JA, Clumeck N, Costagliola D, Daar ES, Echeverría P, Gisslén M, Huedo-Medina TB, Hughes MD, Huppler Hullsiek K, Khabo P, Komati S, Kumar P, Lockman S, MacArthur RD, Maggiolo F, Matteelli A, Miro JM, Oka S, Petoumenos K, Puls RL, Riddler SA, Sax PE, Sierra-Madero J, Torti C, Lundgren JD.

Clin Infect Dis. 2016 Jul 15;63(2):268-80. doi: 10.1093/cid/ciw236. Epub 2016 Apr 18. Review.

16.

Unusual Suspects in the Twilight Zone Between the Hsp90 Interactome and Carcinogenesis.

Vartholomaiou E, Echeverría PC, Picard D.

Adv Cancer Res. 2016;129:1-30. doi: 10.1016/bs.acr.2015.08.001. Epub 2015 Oct 23. Review.

PMID:
26915999
17.

A Remodeled Hsp90 Molecular Chaperone Ensemble with the Novel Cochaperone Aarsd1 Is Required for Muscle Differentiation.

Echeverría PC, Briand PA, Picard D.

Mol Cell Biol. 2016 Mar 31;36(8):1310-21. doi: 10.1128/MCB.01099-15. Print 2016 Apr.

18.

RUNX1 and FOXP3 interplay regulates expression of breast cancer related genes.

Recouvreux MS, Grasso EN, Echeverria PC, Rocha-Viegas L, Castilla LH, Schere-Levy C, Tocci JM, Kordon EC, Rubinstein N.

Oncotarget. 2016 Feb 9;7(6):6552-65. doi: 10.18632/oncotarget.6771.

19.

Polymorphisms in LPL, CETP, and HL protect HIV-infected patients from atherogenic dyslipidemia in an allele-dose-dependent manner.

Guardiola M, Echeverria P, González M, Vallvé JC, Puig J, Clotet B, Ribalta J, Negredo E.

AIDS Res Hum Retroviruses. 2015 Sep;31(9):882-8. doi: 10.1089/AID.2015.0061. Epub 2015 Jul 20.

PMID:
26101956
20.

Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years.

Negredo E, Bonjoch A, Pérez-Álvarez N, Ornelas A, Puig J, Herrero C, Estany C, del Río L, di Gregorio S, Echeverría P, Clotet B.

HIV Med. 2015 Aug;16(7):441-8. doi: 10.1111/hiv.12260. Epub 2015 May 6.

21.

Long-term changes in bone mineral density after switching to a protease inhibitor monotherapy in HIV-infected subject.

Negredo E, Bonjoch A, Puig J, Echeverría P, Estany C, Santos JR, Moltó J, Pérez-Álvarez N, Ornelas A, Clotet B.

New Microbiol. 2015 Apr;38(2):193-9. Epub 2015 Apr 29.

22.

Ten-Year Safety with Polyacrylamide Gel Used to Correct Facial Lipoatrophy in HIV-Infected Patients.

Negredo E, Puig J, Ornelas A, Echeverría P, Bonjoch A, Estany C, Higueras C, Gonzalez-Mestre V, Clotet B.

AIDS Res Hum Retroviruses. 2015 Aug;31(8):817-21. doi: 10.1089/AID.2015.0004. Epub 2015 May 5.

PMID:
25858612
23.

Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels.

Negredo E, Diez-Pérez A, Bonjoch A, Domingo P, Pérez-Álvarez N, Gutierrez M, Mateo G, Puig J, Echeverría P, Escrig R, Clotet B.

J Antimicrob Chemother. 2015 Jul;70(7):2104-7. doi: 10.1093/jac/dkv063. Epub 2015 Mar 13.

PMID:
25769303
24.

Heck coupling using a vinyliodo-MIDA boronate: an efficient and modular access to polyene frameworks.

Cornil J, Echeverria PG, Phansavath P, Ratovelomanana-Vidal V, Guérinot A, Cossy J.

Org Lett. 2015 Feb 20;17(4):948-51. doi: 10.1021/acs.orglett.5b00042. Epub 2015 Feb 2.

PMID:
25642893
25.

An interplay between the p38 MAPK pathway and AUBPs regulates c-fos mRNA stability during mitogenic stimulation.

Degese MS, Tanos T, Naipauer J, Gingerich T, Chiappe D, Echeverria P, LaMarre J, Gutkind JS, Coso OA.

Biochem J. 2015 Apr 1;467(1):77-90. doi: 10.1042/BJ20141100.

PMID:
25588078
26.

Association between polymorphisms in genes involved in lipid metabolism and immunological status in chronically HIV-infected patients.

Echeverria P, Guardiola M, González M, Vallvé JC, Bonjoch A, Puig J, Clotet B, Ribalta J, Negredo E.

Antiviral Res. 2015 Feb;114:48-52. doi: 10.1016/j.antiviral.2014.12.002. Epub 2014 Dec 8.

PMID:
25500319
27.

Polymorphisms in LPL, CETP, and HL protect HIV-infected patients from atherogenic dyslipidemia in an allele-dose-dependent manner.

Echeverría P, Guardiola M, González M, Vallvé JC, Puig J, Bonjoch A, Clotet B, Ribalta J, Negredo E.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19557. doi: 10.7448/IAS.17.4.19557. eCollection 2014.

28.

Association between lipid genetic and immunological status in chronically HIV-infected patients.

Echeverría P, Guardiola M, González M, Vallvé JC, Puig J, Bonjoch A, Clotet B, Ribalta J, Negredo E.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19555. doi: 10.7448/IAS.17.4.19555. eCollection 2014.

29.

High prevalence of signs of renal damage despite normal renal function in a cohort of HIV-infected patients: evaluation of associated factors.

Bonjoch A, Juega J, Puig J, Pérez-Alvarez N, Aiestarán A, Echeverría P, Pérez V, Clotet B, Romero R, Bonet J, Negredo E.

AIDS Patient Care STDS. 2014 Oct;28(10):524-9. doi: 10.1089/apc.2014.0172. Epub 2014 Sep 19.

PMID:
25238104
30.

Prevalence of ischemic heart disease and management of coronary risk in daily clinical practice: results from a Mediterranean cohort of HIV-infected patients.

Echeverría P, Domingo P, Llibre JM, Gutierrez M, Mateo G, Puig J, Bonjoch A, Pérez-Alvarez N, Sirera G, Clotet B, Negredo E.

Biomed Res Int. 2014;2014:823058. doi: 10.1155/2014/823058. Epub 2014 Aug 7.

31.

Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study).

Negredo E, Domingo P, Pérez-Álvarez N, Gutiérrez M, Mateo G, Puig J, Escrig R, Echeverría P, Bonjoch A, Clotet B.

J Antimicrob Chemother. 2014 Dec;69(12):3368-71. doi: 10.1093/jac/dku300. Epub 2014 Aug 13.

PMID:
25125679
32.

Synthetic strategy toward the C44-C65 fragment of mirabalin.

Echeverria PG, Prévost S, Cornil J, Férard C, Reymond S, Guérinot A, Cossy J, Ratovelomanana-Vidal V, Phansavath P.

Org Lett. 2014 May 2;16(9):2390-3. doi: 10.1021/ol500720j. Epub 2014 Apr 11.

PMID:
24725196
33.

Protozoan HSP90-heterocomplex: molecular interaction network and biological significance.

Figueras MJ, Echeverria PC, Angel SO.

Curr Protein Pept Sci. 2014 May;15(3):245-55. Review.

PMID:
24694366
34.

Toxoplasma gondii Hsp90: potential roles in essential cellular processes of the parasite.

Angel SO, Figueras MJ, Alomar ML, Echeverria PC, Deng B.

Parasitology. 2014 Aug;141(9):1138-47. doi: 10.1017/S0031182014000055. Epub 2014 Feb 21. Review.

35.

Randomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study.

Echeverría P, Bonjoch A, Puig J, Moltó J, Paredes R, Sirera G, Ornelas A, Pérez-Álvarez N, Clotet B, Negredo E.

PLoS One. 2014 Feb 4;9(2):e84676. doi: 10.1371/journal.pone.0084676. eCollection 2014.

36.

Dynamic impacts of the inhibition of the molecular chaperone Hsp90 on the T-cell proteome have implications for anti-cancer therapy.

Fierro-Monti I, Echeverria P, Racle J, Hernandez C, Picard D, Quadroni M.

PLoS One. 2013 Nov 27;8(11):e80425. doi: 10.1371/journal.pone.0080425. eCollection 2013.

37.

Peak bone mass in young HIV-infected patients compared with healthy controls.

Negredo E, Domingo P, Ferrer E, Estrada V, Curran A, Navarro A, Isernia V, Rosales J, Pérez-Álvarez N, Puig J, Bonjoch A, Echeverría P, Podzamczer D, Clotet B.

J Acquir Immune Defic Syndr. 2014 Feb 1;65(2):207-12. doi: 10.1097/01.qai.0000435598.20104.d6.

PMID:
24091689
38.

Pulse wave velocity as index of arterial stiffness in HIV-infected patients compared with a healthy population.

Echeverría P, Bonjoch A, Moltó J, Jou A, Puig J, Ornelas A, Pérez-Álvarez N, Clotet B, Negredo E.

J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):50-6. doi: 10.1097/QAI.0b013e3182a97c17.

PMID:
23982659
39.

Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy.

Negredo E, Massanella M, Puertas MC, Buzón MJ, Puig J, Pérez-Alvárez N, Pérez-Santiago J, Bonjoch A, Moltó J, Jou A, Echeverría P, Llibre JM, Martínez-Picado J, Clotet B, Blanco J.

J Antimicrob Chemother. 2013 Oct;68(10):2358-62. doi: 10.1093/jac/dkt183. Epub 2013 May 14.

40.

Progesterone/RANKL is a major regulatory axis in the human breast.

Tanos T, Sflomos G, Echeverria PC, Ayyanan A, Gutierrez M, Delaloye JF, Raffoul W, Fiche M, Dougall W, Schneider P, Yalcin-Ozuysal O, Brisken C.

Sci Transl Med. 2013 Apr 24;5(182):182ra55. doi: 10.1126/scitranslmed.3005654.

41.

Clinical and microbiological aspects of acute community-acquired pneumonia due to Streptococcus pneumoniae.

Cardinal-Fernández P, García Gabarrot G, Echeverria P, Zum G, Hurtado J, Rieppi G.

Rev Clin Esp (Barc). 2013 Mar;213(2):88-96. doi: 10.1016/j.rce.2012.09.011. Epub 2012 Nov 22. English, Spanish.

PMID:
23178082
42.

A review of recent patents on the protozoan parasite HSP90 as a drug target.

Angel SO, Matrajt M, Echeverria PC.

Recent Pat Biotechnol. 2013 Apr;7(1):2-8. Review.

43.

High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy.

Bonjoch A, Echeverría P, Perez-Alvarez N, Puig J, Estany C, Clotet B, Negredo E.

Antiviral Res. 2012 Oct;96(1):65-9. doi: 10.1016/j.antiviral.2012.07.009. Epub 2012 Aug 6.

PMID:
22892171
44.

ER and PR signaling nodes during mammary gland development.

Tanos T, Rojo L, Echeverria P, Brisken C.

Breast Cancer Res. 2012 Jul 19;14(4):210. doi: 10.1186/bcr3166. Review.

45.

Toxoplasma gondii Sis1-like J-domain protein is a cytosolic chaperone associated to HSP90/HSP70 complex.

Figueras MJ, Martin OA, Echeverria PC, de Miguel N, Naguleswaran A, Sullivan WJ Jr, Corvi MM, Angel SO.

Int J Biol Macromol. 2012 Apr 1;50(3):725-33. doi: 10.1016/j.ijbiomac.2011.12.012. Epub 2011 Dec 23.

46.

An interaction network predicted from public data as a discovery tool: application to the Hsp90 molecular chaperone machine.

Echeverría PC, Bernthaler A, Dupuis P, Mayer B, Picard D.

PLoS One. 2011;6(10):e26044. doi: 10.1371/journal.pone.0026044. Epub 2011 Oct 11.

47.

Detection of changes in gene regulatory patterns, elicited by perturbations of the Hsp90 molecular chaperone complex, by visualizing multiple experiments with an animation.

Echeverría PC, Forafonov F, Pandey DP, Mühlebach G, Picard D.

BioData Min. 2011 Jun 14;4(1):15. doi: 10.1186/1756-0381-4-15.

48.

Candida prophylaxis and therapy in the ICU.

Echeverria PM, Kett DH, Azoulay E.

Semin Respir Crit Care Med. 2011 Apr;32(2):159-73. doi: 10.1055/s-0031-1275528. Epub 2011 Apr 19. Review.

PMID:
21506052
49.

Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study.

Kett DH, Azoulay E, Echeverria PM, Vincent JL; Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators.

Crit Care Med. 2011 Apr;39(4):665-70. doi: 10.1097/CCM.0b013e318206c1ca.

PMID:
21169817
50.

Role of molecular chaperones and TPR-domain proteins in the cytoplasmic transport of steroid receptors and their passage through the nuclear pore.

Galigniana MD, Echeverría PC, Erlejman AG, Piwien-Pilipuk G.

Nucleus. 2010 Jul-Aug;1(4):299-308. doi: 10.4161/nucl.1.4.11743.

Supplemental Content

Loading ...
Support Center